Navigation Links
Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study,Results at the American Society of Clinical Oncology Annual Meeting

logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms S-3 (File No. 333-134945) and S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC.

Contact

For Investors:
TS Communications Group, LLC
Tara Spiess / Andrea Romstad
914-921-5900
or
For Media:
Feinstein Kean Healthcare
H
'"/>




Page: 1 2 3

Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ... corporate offices in Aliso Viejo , ... due to the tremendous growth and worldwide expansion, a ... of patented SnoreRx, the anti snore cure have exceeded ... said, "We are now in 23 countries and ...
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... , SAN DIEGO, Dec. 15 Volcano Corporation ... intravascular therapy guidance tools - including Fractional Flow Reserve ... Coherence Tomography (OCT) - designed to enhance the diagnosis ... today the placement of over 2,500 s5 family consoles ...
... CITY, Dec. 15 Sonic Innovations, Inc. (Sonic), a Utah-based ... to its local Feeding America network member food bank on ... presented the $10,000 check to the local Feeding America member, ... City location. Sonic employees also participated in an office food ...
Cached Medicine Technology:Volcano Announces Installed Base Growth Milestone 2Volcano Announces Installed Base Growth Milestone 3Volcano Announces Installed Base Growth Milestone 4Volcano Announces Installed Base Growth Milestone 5Sonic Innovations, Inc. Donates $10,000 to Feeding America 2
(Date:12/24/2014)... Oregon (PRWEB) December 24, 2014 ... Rehab sat down with Derek Fenwick, PT, MBA, ... changes that will stem from the passing of the ... (IMPACT Act). In this taping of the Infinicast, ... title XVIII of the Social Security Act to standardize ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... the American Diabetes Association (ADA) call for giving the cholesterol-lowering ... help prevent heart disease. These new standards bring the ... American Heart Association, which also recommend giving low- or high-dose ... people with diabetes. "We agree that the decision to ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 24, 2014 ... COC Industry is a professional and in-depth research ... the report introduces COC basic information, including its ... policy analysis, news analysis, etc. This report also ... structure etc. Production is separated by regions, technology ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dental implants ... for a tooth replacement. They offer the strongest and ... advantages over other forms of tooth replacement. They will ... on the adjacent teeth for support, and they prevent ... have been told that they are not suitable candidates ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2
... Medical School in New Brunswick, New Jersey have reported ... in bed wetting //as children since they seem to ... plausibility in inferring that breast-feeding protects against bed-wetting and ... said. They added that there was sufficient evidence that ...
... China, doctors have successfully transplanted the heart of a ... from people whom Chinese traditionally do not consider dead. ... heart extracted from a brain-dead patient, the surgery is ... of Institute of Organ Transplantation of Tongji Hospital under ...
... in Meghalaya so far this year, state Health minister E ... to a calling attention notice, Marak said 11 deaths were ... from East Garo Hills, nine died in West Khasi, four ... ,This year, there has been a "more serious" incidence of ...
... that pig fever had been diagnosed and was the cause ... is believed to be the first reported case of the ... to the death of pigs by the Indian Veterinary Research ... said Divakaran. ,Reports indicate that initially the owner ...
... because heat is capable of relieving pain, say researchers from ... scientists were able to understand the behavior of pain receptors ... has a pain relieving effect. Scientists rated the benefits of ... because pain receptors are turned off at the molecular level, ...
... Alexander Downer has sanctioned $17 million to take the ... tuberculosis and malaria. ,To quote Mr. Downer, "Global ... people to be treated with anti-retroviral drugs for HIV, ... tuberculosis. More than 11 million insecticide-treated bed nets have ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: